Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
15,213 questions in 2,394 reviews
current versionsNo studies 15,213 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Home‐based record combined with other interventions vs routine care Occurrence of vaccine‐preventable diseases · children aged 1 year Interventions for improving coverage of childhood immunisation in low‐ and middle‐income countries (2023) · Cochrane | no estimate extracted | NR | No studies |
Home‐based record combined with other interventions vs routine care Cost of the intervention presented narratively in 2 studies · children aged 1 year Interventions for improving coverage of childhood immunisation in low‐ and middle‐income countries (2023) · Cochrane | no estimate extracted | NR | No studies |
Home‐based record combined with other interventions vs routine care Adverse events · children aged 1 year Interventions for improving coverage of childhood immunisation in low‐ and middle‐income countries (2023) · Cochrane | no estimate extracted | NR | No studies |
Digital register vs routine care Proportion of children under 5 years of age fully immunised with all scheduled vaccines · children under 5 years of age Interventions for improving coverage of childhood immunisation in low‐ and middle‐income countries (2023) · Cochrane | no estimate extracted | NR | No studies |
Digital register vs routine care Occurrence of vaccine‐preventable diseases · children under 5 years of age Interventions for improving coverage of childhood immunisation in low‐ and middle‐income countries (2023) · Cochrane | no estimate extracted | NR | No studies |
Digital register vs routine care Cost of the intervention · children under 5 years of age Interventions for improving coverage of childhood immunisation in low‐ and middle‐income countries (2023) · Cochrane | no estimate extracted | NR | No studies |
Digital register vs routine care Adverse events · children under 5 years of age Interventions for improving coverage of childhood immunisation in low‐ and middle‐income countries (2023) · Cochrane | no estimate extracted | NR | No studies |
Phone call/SMS with/without combination with monetary incentives vs routine care Occurrence of vaccine‐preventable diseases · children under 5 years of age Interventions for improving coverage of childhood immunisation in low‐ and middle‐income countries (2023) · Cochrane | no estimate extracted | NR | No studies |
Phone call/SMS with/without combination with monetary incentives vs routine care Cost of the intervention ‐ reported narratively for 2 studiesk · children under 5 years of age Interventions for improving coverage of childhood immunisation in low‐ and middle‐income countries (2023) · Cochrane | no estimate extracted | NR | No studies |
Phone call/SMS with/without combination with monetary incentives vs routine care Adverse events · children under 5 years of age Interventions for improving coverage of childhood immunisation in low‐ and middle‐income countries (2023) · Cochrane | no estimate extracted | NR | No studies |
Wearable reminders vs routine care Proportion of children who received all recommended vaccines by 2 years of age · children under 5 years of age Interventions for improving coverage of childhood immunisation in low‐ and middle‐income countries (2023) · Cochrane | no estimate extracted | NR | No studies |
Wearable reminders vs routine care Proportion of children under 5 years of age fully immunised with all scheduled vaccines · children under 5 years of age Interventions for improving coverage of childhood immunisation in low‐ and middle‐income countries (2023) · Cochrane | no estimate extracted | NR | No studies |
Wearable reminders vs routine care Occurrence of vaccine‐preventable diseases · children under 5 years of age Interventions for improving coverage of childhood immunisation in low‐ and middle‐income countries (2023) · Cochrane | no estimate extracted | NR | No studies |
Wearable reminders vs routine care Cost of the intervention ‐ reported narratively for 1 study · children under 5 years of age Interventions for improving coverage of childhood immunisation in low‐ and middle‐income countries (2023) · Cochrane | no estimate extracted | NR | No studies |
Wearable reminders vs routine care Adverse events · children under 5 years of age Interventions for improving coverage of childhood immunisation in low‐ and middle‐income countries (2023) · Cochrane | no estimate extracted | NR | No studies |
Training of health providers vs routine care Proportion of children who received DTP3 or Penta 3 by 1 year of age · children under the age of 5 years Interventions for improving coverage of childhood immunisation in low‐ and middle‐income countries (2023) · Cochrane | no estimate extracted | NR | No studies |
Training of health providers vs routine care Proportion of children who received the vaccine under study (BCG) · children under the age of 5 years Interventions for improving coverage of childhood immunisation in low‐ and middle‐income countries (2023) · Cochrane | no estimate extracted | NR | No studies |
Training of health providers vs routine care Proportion of children under 5 years of age fully immunised with all scheduled vaccines · children under the age of 5 years Interventions for improving coverage of childhood immunisation in low‐ and middle‐income countries (2023) · Cochrane | no estimate extracted | NR | No studies |
Training of health providers vs routine care Occurrence of vaccine‐preventable diseases · children under the age of 5 years Interventions for improving coverage of childhood immunisation in low‐ and middle‐income countries (2023) · Cochrane | no estimate extracted | NR | No studies |
Training of health providers vs routine care Cost of the intervention · children under the age of 5 years Interventions for improving coverage of childhood immunisation in low‐ and middle‐income countries (2023) · Cochrane | no estimate extracted | NR | No studies |
Training of health providers vs routine care Adverse events · children under the age of 5 years Interventions for improving coverage of childhood immunisation in low‐ and middle‐income countries (2023) · Cochrane | no estimate extracted | NR | No studies |
Home visit vs routine care Proportion of children who received DTP3 or Penta 3 by 1 year of age · children under 5 years of age Interventions for improving coverage of childhood immunisation in low‐ and middle‐income countries (2023) · Cochrane | no estimate extracted | NR | No studies |
Home visit vs routine care Number of children under 5 years of age fully immunised with all scheduled vaccines ‐ not reported · children under 5 years of age Interventions for improving coverage of childhood immunisation in low‐ and middle‐income countries (2023) · Cochrane | no estimate extracted | NR | No studies |
Home visit vs routine care Occurrence of vaccine‐preventable diseases · children under 5 years of age Interventions for improving coverage of childhood immunisation in low‐ and middle‐income countries (2023) · Cochrane | no estimate extracted | NR | No studies |
Home visit vs routine care Cost of the intervention · children under 5 years of age Interventions for improving coverage of childhood immunisation in low‐ and middle‐income countries (2023) · Cochrane | no estimate extracted | NR | No studies |
Home visit vs routine care Adverse events · children under 5 years of age Interventions for improving coverage of childhood immunisation in low‐ and middle‐income countries (2023) · Cochrane | no estimate extracted | NR | No studies |
Immunisation outreach vs routine care Occurrence of vaccine‐preventable diseases · children under 5 years of age Interventions for improving coverage of childhood immunisation in low‐ and middle‐income countries (2023) · Cochrane | no estimate extracted | NR | No studies |
Immunisation outreach vs routine care Cost of the intervention ‐ reported narratively in one studyc · children under 5 years of age Interventions for improving coverage of childhood immunisation in low‐ and middle‐income countries (2023) · Cochrane | no estimate extracted | NR | No studies |
Immunisation outreach vs routine care Adverse events · children under 5 years of age Interventions for improving coverage of childhood immunisation in low‐ and middle‐income countries (2023) · Cochrane | no estimate extracted | NR | No studies |
Integration of immunisation with other health services vs routine care Proportion of children under 5 years of age fully immunised with all scheduled vaccines · children under 5 years of age Interventions for improving coverage of childhood immunisation in low‐ and middle‐income countries (2023) · Cochrane | no estimate extracted | NR | No studies |
Integration of immunisation with other health services vs routine care Occurrence of vaccine‐preventable diseases · children under 5 years of age Interventions for improving coverage of childhood immunisation in low‐ and middle‐income countries (2023) · Cochrane | no estimate extracted | NR | No studies |
Integration of immunisation with other health services vs routine care Cost of the intervention · children under 5 years of age Interventions for improving coverage of childhood immunisation in low‐ and middle‐income countries (2023) · Cochrane | no estimate extracted | NR | No studies |
Integration of immunisation with other health services vs routine care Adverse events · children under 5 years of age Interventions for improving coverage of childhood immunisation in low‐ and middle‐income countries (2023) · Cochrane | no estimate extracted | NR | No studies |
Engagement of community leaders vs routine care Proportion of children who received all recommended vaccines by 2 years of age · children under 5 years of age Interventions for improving coverage of childhood immunisation in low‐ and middle‐income countries (2023) · Cochrane | no estimate extracted | NR | No studies |
First‐line thiazides vs first‐line ACE inhibitors Total serious adverse events · adults with hypertension First‐line diuretics versus other classes of antihypertensive drugs for hypertension (2023) · Cochrane | no estimate extracted | NR | No studies |
First‐line thiazides vs first‐line beta‐blockers Total serious adverse events · adults with hypertension First‐line diuretics versus other classes of antihypertensive drugs for hypertension (2023) · Cochrane | no estimate extracted | NR | No studies |
First‐line thiazides vs first‐line alpha‐blockers Total serious adverse events · adults with hypertension First‐line diuretics versus other classes of antihypertensive drugs for hypertension (2023) · Cochrane | no estimate extracted | NR | No studies |
Esomeprazole vs placebo Adverse events ‐ not reported · GORD in infants Pharmacological treatment of gastro‐oesophageal reflux in children (2023) · Cochrane | no estimate extracted | NR | No studies |
Esomeprazole vs placebo pH indices ‐ not measured · GORD in infants Pharmacological treatment of gastro‐oesophageal reflux in children (2023) · Cochrane | no estimate extracted | NR | No studies |
Esomeprazole vs placebo Endoscopic metrics ‐ not measured · GORD in infants Pharmacological treatment of gastro‐oesophageal reflux in children (2023) · Cochrane | no estimate extracted | NR | No studies |
Rabeprazole at higher doses (1 mg/kg) vs rabeprazole at lower doses (0.5 mg/kg) pH indices ‐ not measured · GORD in children over 1 year of age Pharmacological treatment of gastro‐oesophageal reflux in children (2023) · Cochrane | no estimate extracted | NR | No studies |
Pantoprazole in higher doses (1.2 mg/kg) vs pantoprazole at lower doses (0.3 mg/kg) Improvement in pH indices ‐ not measured · GORD in children over 1 year of age Pharmacological treatment of gastro‐oesophageal reflux in children (2023) · Cochrane | no estimate extracted | NR | No studies |
Omeprazole vs placebo Adverse events ‐ not reported · infants with GORD Pharmacological treatment of gastro‐oesophageal reflux in children (2023) · Cochrane | no estimate extracted | NR | No studies |
Pantoprazole in higher doses (1.2 mg/kg) vs pantoprazole at lower doses (0.3 mg/kg) Improvement in endoscopic metrics ‐ not measured · GORD in children over 1 year of age Pharmacological treatment of gastro‐oesophageal reflux in children (2023) · Cochrane | no estimate extracted | NR | No studies |
Omeprazole vs placebo Endoscopic metrics ‐ not measured · infants with GORD Pharmacological treatment of gastro‐oesophageal reflux in children (2023) · Cochrane | no estimate extracted | NR | No studies |
Omeprazole vs ranitidine Adverse events in infants ‐ not measured · GORD in infants Pharmacological treatment of gastro‐oesophageal reflux in children (2023) · Cochrane | no estimate extracted | NR | No studies |
Omeprazole vs ranitidine Improvement in pH metrics in infants ‐ not measured · GORD in infants Pharmacological treatment of gastro‐oesophageal reflux in children (2023) · Cochrane | no estimate extracted | NR | No studies |
Omeprazole vs ranitidine Improvement in endoscopic findings in infants ‐ not measured · GORD in infants Pharmacological treatment of gastro‐oesophageal reflux in children (2023) · Cochrane | no estimate extracted | NR | No studies |
Statin vs placebo Resumption of spontaneous ovulation · women with polycystic ovary syndrome not actively trying to conceive Statins for women with polycystic ovary syndrome not actively trying to conceive (2023) · Cochrane | no estimate extracted | NR | No studies |
Statin vs metformin Resumption of spontaneous ovulation · women with polycystic ovary syndrome not actively trying to conceive Statins for women with polycystic ovary syndrome not actively trying to conceive (2023) · Cochrane | no estimate extracted | NR | No studies |